Enhancement of oral bioavailability of Rivastigmine (cas 123441-03-2) with quercetin nanoparticles by inhibiting CYP3A4 and esterases

Add time:07/22/2019    Source:sciencedirect.com

BackgroundQuercetin is a well-known flavonoid, has pharmacokinetic interaction with ester drugs due to its capability of esterase inhibition in the gut and liver. However, the interaction between quercetin nanoparticles (NQC) and Rivastigmine (cas 123441-03-2) has not been reported. Hence, the present study was performed to evaluate the effect of quercetin alone and its nanoparticles on the pharmacokinetics of rivastigmine in rats.

We also recommend Trading Suppliers and Manufacturers of Rivastigmine (cas 123441-03-2). Pls Click Website Link as below: cas 123441-03-2 suppliers

Prev:Spectrodensitometric determination of Rivastigmine (cas 123441-03-2) after vortex assisted magnetic solid phase extraction
Next:Paroxetine and Rivastigmine (cas 123441-03-2) mitigates adjuvant-induced rheumatoid arthritis in rats: Impact on oxidative stress, apoptosis and RANKL/OPG signals)